Redeye provides a research update following the Q1 report recently published by Initiator Pharma.
Redeye provides a research update following Catella’s Q1 2025 report.
CapMan posted a solid set of Q1 numbers, with fee income growing 8% y/y, roughly in line with our ex...
Redeye provides a brief comment on the news that 85% of the TO 12 warrant program has been secured a...
- Investments in sales held back margins in Q1... - .
Ahead of Relais Q1, we maintain our estimates intact.
Redeye is optimistic about Alligator’s completion of GMP production of mitazalimab, a precondition f...
Redeye notes an exceptionally strong Q1 with record sales.
Balanced regional growth with broad-based support from the Medical Device segment.
Redeye updates on W5 Solutions following a softer than expected Q1-report.
Sales 9% below us, but partly temporary; orders grew 61% Mixed outlook, reiterates guidance, but cit...
Redeye provides an update following Truecaller’s Q1 2025 report, which came in softer than expected.
Redeye noted that BeammWave's Q1 2025 report significantly exceeded expectations, primarily due to r...
Redeye notes that Sivers’ Q1 2025 report was strong, with another quarter of record net sales reachi...
Redeye comments on Active Biotech’s Q1 report 2025.
